Ipsen Surges 4.55% Boosted by FDA Status and Promising Clinical Data
Ipsen advances 4.55% to 133.30 euros this Wednesday, breaking through its resistance at 131.60 euros following the FDA's Breakthrough Therapy designation for its antibody IPN60340 in acute myeloid leukemia and the presentation of promising clinical data at the TOXINS 2026 congress.
Stock Performance and Technical Analysis
Ipsen's stock price is up 4.55% at 133.30 euros this Wednesday midday, after closing at 127.50 euros the previous day. The stock thus surpasses the previously identified resistance level of 131.60 euros and continues its upward trajectory above its moving averages, including the MM50 at 123.73 euros and the MM200 at 111.87 euros. This positive momentum is part of a broader movement, with a 10.17% increase over seven days and a 15.91% increase over three months, reflecting a marked resurgence of interest in the stock. Technically, the RSI is at 67, indicating positive momentum without reaching the overbought zone, while the MACD indicator displays a strongly positive histogram at 1.33, confirming a solid upward trend. The stock is now trading above the upper Bollinger band, located at 128.36 euros, indicating an acceleration of movement and increased short-term volatility.
FDA Breakthrough Therapy Designation
The U.S. Food and Drug Administration granted Breakthrough Therapy designation to IPN60340 on January 13th, an experimental monoclonal antibody developed by Ipsen in combination with venetoclax and azacitidine, for the first-line treatment of acute myeloid leukemia in patients ineligible for intensive chemotherapy. This status, which aims to expedite the development and review of drugs intended for serious diseases, is based on the results of the phase I/II trial named EVICTION. Data presented at the American Society of Hematology congress involving 57 patients showed nearly double the complete response rate compared to historical data from standard management, with good tolerance of the therapeutic combination.
